Histopathologic Patterns of Ovarian Masses in a University Teaching Hospital
Authors/Creators
- 1. Tutor, Department of Pathology, Patna Medical College and Hospital, Patna, Bihar, India
- 2. Professor, Department of Pathology, Patna Medical College and Hospital, Patna, Bihar, India
- 3. Professor and HOD, Department of Pathology, Patna Medical College and Hospital, Patna, Bihar, India
Description
This retrospective study examines the histopathologic patterns of ovarian masses in 87 patients treated at Patna Medical College and Hospital from January 2019 to July 2021. The analysis reveals that 64.4% of the masses were benign, predominantly serous and mucinous cystadenomas, while 20.7% were malignant, with serous adenocarcinoma being the most common. Borderline tumors accounted for 14.9% of the cases. The study found a notable correlation between patient age and the type of ovarian mass, with benign lesions more common in patients under 50 and malignant or borderline tumors more frequent in those over 50. These findings underscore the critical role of histopathologic evaluation in the diagnosis and management of ovarian masses, emphasizing the need for tailored screening and treatment strategies.
Abstract (English)
This retrospective study examines the histopathologic patterns of ovarian masses in 87 patients treated at Patna Medical College and Hospital from January 2019 to July 2021. The analysis reveals that 64.4% of the masses were benign, predominantly serous and mucinous cystadenomas, while 20.7% were malignant, with serous adenocarcinoma being the most common. Borderline tumors accounted for 14.9% of the cases. The study found a notable correlation between patient age and the type of ovarian mass, with benign lesions more common in patients under 50 and malignant or borderline tumors more frequent in those over 50. These findings underscore the critical role of histopathologic evaluation in the diagnosis and management of ovarian masses, emphasizing the need for tailored screening and treatment strategies.
Files
IJPCR,Vol16,Issue5,Article470.pdf
Files
(1.6 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:98e472ab4d4cf3238377d7a079fcd1fa
|
1.6 MB | Preview Download |
Additional details
Dates
- Accepted
-
2024-05-15
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue5,Article470.pdf
- Development Status
- Active
References
- 1. Kurman RJ, Shih I-M. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. Am J Surg Pathol. 2010 Mar;34(3):433-43. 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan; 69 (1):7-34. 3. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012 Mar;460(3):237-49. 4. Seidman JD, Yemelyanova AV, Zaino RJ, Kurman RJ, Ronnett BM. The Distribution of Serous Tubal Intraepithelial Carcinoma (STIC): An Analysis of 300 Prophylactic Salpingo-Oophorectomies from Women with BRCA Mutations. Mod Pathol. 2011 Jan;24 (1):31-9. 5. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:61-85. 6. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011 Mar-Apr;61(3):183- 203. 7. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000 Mar-Apr;19(1):3-10. 8. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92. 9. Cho KR, Shih I-M. Ovarian cancer. Annu Rev Pathol. 2009; 4:287-313. 10. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014 Nov;133(3):401-4. 11. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010 Nov;10(11):803-8. 12. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Oct; 11 (10):719-25. 13. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009 Jun;9(6): 415-28. 14. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001 Apr;22(2):255-88. 15. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol. 2012 Jan;124(1):176- 80. 16. Kaldawy A, Segev Y, Lavie O, Auslender R, Shushan A. Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016 Sep;143 (2) :433-8. 17. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010; 2010:932371. 18. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and Type II. Biomed Res Int. 2014; 2014 :93 4261. 19. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep;177(3):10 53-64. 20. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 Oct; 41:3-14.